Peter Joyce - founding a virtual biotech
The Bioinformatics CRO Podcast
00:00
Introduction
Gray Wolf is a company developing small molecule inhibitors of two enzymes called E-Rap1 and E-RAP2. By inhibiting these enzymes, we're aiming to increase tumor visibility to the immune system so that we can promote the attack and destruction of cancers. If successful, where would this fit in the menagerie of oncology drugs? Yes, it's a good question because immunocology is certainly a very exciting and hot space.
Play episode from 00:00
Transcript
